ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Economics"

  • 2018 American Transplant Congress

    Private Insurance is Associated with Reduce Access to HCV Therapy after Liver Transplantation

    D. Axelrod,1 M. Schnitzler,2 B. Kasiske,3 G. Hess,4 R. Bloom,5 F. Gordon,1 H. Randall,2 K. Lentine.2

    1Lahey Clinic, Burlington; 2Saint Louis U, St. Louis; 3SRTR, Minneapolis; 4Symphony Health, Conshohocken; 5U Penn, Philadelphia.

    Effective treatment for hepatitis C virus (HCV) infection has revolutionized post liver transplant (LTx) care. Administration of direct-acting antiviral agents (DAAs) after HCV+ LTx results…
  • 2018 American Transplant Congress

    Cost Analysis of Loco-Regional Bridging Therapy for Hepatocellular Carcinoma: A National Study

    M. Nazzal,1 R. Ouseph,1 X. Huiling,1 M. Schnitzler,1 C. Varma,1 H. Randall,1 J. Tuttle-Newhall,2 D. Axelrod,3 K. Lentine.1

    1Abdominal Transplant, Saint Louis University Hospital, Saint Louis, MO; 2Surgery, East Carolina University/Brody School of Medicine, Greenville, NC.

    Liver transplantation (LT) is cost-effective in the primary treatment of Hepatocellular carcinoma (HCC). Loco-regional therapies (LRTs) have increased as both primary therapy for HCC as…
  • 2018 American Transplant Congress

    Health and Economic Disparities in Waitlist Access and Liver Distribution Policy

    R. Lynch,1 K. Ross,1 T. Pearson,1 D. Goldberg,2 R. Patzer.1

    1Surgery, Emory University, Atlanta, GA; 2Hepatology, University of Pennsylvania, Philadelphia, PA.

    Background:Sociodemographic disparities compound mortality on the liver transplant waitlist, but the relevance of waitlist disparities to mortality and access among the general population remains unclear.Methods:…
  • 2018 American Transplant Congress

    Analysis of NIH Research Funding in Transplantation: The Important Impact of Physician-Scientists in Abdominal Transplant Research

    A. Narahari, J. Mehaffey, A. Chandrabhatla, P. Baderdinni, L. Kron, K. Brayman.

    Surgery, University of Virginia, Charlottesville, VA.

    Introduction: Obtaining National Institutes of Health (NIH) funding for scientific research has become increasingly difficult. With increasing clinical demands and declining NIH funding, performing research…
  • 2018 American Transplant Congress

    The Financial Impact of the Opioid Epidemic on Kidney Transplantation Readmissions

    L. Wilson, D. Taber, N. Pilch, R. Gilbert, Z. Elmaasarani, B. O'Brien, N. Patel, P. Mauldin, S. Ball, P. Baliga, J. Fleming.

    MUSC, Charleston, SC.

    Research has demonstrated increased annual medical costs in patients who abuse opioids, estimated at up to $18,000 per patient and $29 billion overall in the…
  • 2018 American Transplant Congress

    Analysis of Cost Effectiveness of Treatment for Acute Antibody-Mediated Rejection

    C. McDermott, K. Carsky, P. Ferrin, A. Gaines, D. Chernobylsky, M. Killackey, A. Paramesh, R. Zhang, J. Buell.

    Tulane University School of Medicine, New Orleans, LA.

    Purpose: Because AMR can be a risk factor for graft loss, the expense created by AMR treatment may be subject to scrutiny in patients who…
  • 2018 American Transplant Congress

    Economic Evaluation of Contemporary Kidney Transplant Practice

    D. Axelrod,1 M. Schnitzler,2 H. Xiao,2 W. Irish,3 J. Tuttle-Newhall,3 S-.H. Chang,4 B. Kasiske,5 T. Alhamad,4 K. Lentine.2

    1Lahey Clinic, Burlington; 2Saint Louis University, St. Louis; 3East Carolina University, Greeneville; 4Washington University, St. Louis; 5Hennepin County, Minneapolis.

    Kidney transplantation (KTx) has been established as the optimal therapy for medically suitable patients with end-stage renal disease, prolonging survival and reducing health care spending.…
  • 2018 American Transplant Congress

    Cost Analysis of Biliary Strictures Following Orthotopic Liver Transplantation in the United States

    J. Jones,1 N. Bhutiani,1 D. Wei,2 L. Goldstein,3 R. Martin,1 C. Jones,1 R. Cannon.1

    1Surgery, University of Louisville, Louisville, KY; 2Real-world Data Analytics and Research, Johnson & Johnson, New Brunswick, NJ; 3Health Economics and Market Access, Ethicon, Inc., Somerville, NJ.

    Introduction: While previous studies have evaluated risk factors, management, and outcomes in patients who develop biliary strictures (BS) after undergoing orthotopic liver transplantation (OLT), none…
  • 2018 American Transplant Congress

    Cost Effectiveness of Hepatitis C Positive Donor Kidney Transplantation for Hepatitis C Negative Recipients with Concomitant Direct-Acting Anti-Viral Therapy

    G. Gupta, Y. Zhang, H. Kale, N. Carroll, R. Sterling.

    Virginia Commonwealth University, Richmond.

    Background: The development of direct acting antiviral (DAA) therapy for hepatitis C virus (HCV) could allow for safe and effective treatment following renal transplantation (RT).…
  • 2018 American Transplant Congress

    Comparative Cost Analysis of ABO-Incompatible Living Kidney Transplantation

    Y. Kakuta,1 M. Okumi,1 K. Unagami,2 M. Furusawa,1 H. Ishida,1 K. Tanabe.1

    1Urology, Tokyo Women's Medical School, Tokyo, Japan; 2Nephrology, Tokyo Women's Medical School, Tokyo, Japan.

    BackgroundABO-incompatible living kidney transplantation (ABO-I) has been accepted as a valid alternative therapy for patients with end-stage kidney disease. The number of ABO-I has been…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 19
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences